LIVSAYIS™ (CEMDISIRAN) APPROVED BY THE FDA AS FIRST AND ONLY SIRNA THERAPY IN GENERALIZED MYASTHENIA GRAVIS AND ONLY TREATMENT WITH FOUR-TIMES-A-YEAR SUBCUTANEOUS DOSING

Reuters · 1d ago

Please log in to view news